Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination
- 30 April 2004
- journal article
- Published by Elsevier in Veterinary Immunology and Immunopathology
- Vol. 98 (3-4) , 127-136
- https://doi.org/10.1016/j.vetimm.2003.11.004
Abstract
No abstract availableKeywords
Funding Information
- Agricultural Experiment Station, New Mexico State University
- Grayson-Jockey Club Research Foundation
- University of Wisconsin-Madison
This publication has 22 references indexed in Scilit:
- Occurrence of infectious upper respiratory tract disease and response to vaccination in horses on six sentinel premises in northern ColoradoEquine Veterinary Journal, 2003
- The Block in Assembly of Modified Vaccinia Virus Ankara in HeLa Cells Reveals New Insights into Vaccinia Virus MorphogenesisJournal of Virology, 2002
- Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA VaccineScience, 2001
- Enhanced Immunogenicity of CD4+T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine TuberculosisInfection and Immunity, 2001
- Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin geneVaccine, 1999
- Local and systemic isotype-specific antibody responses to equine influenza virus infection versus conventional vaccinationVaccine, 1998
- Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.Proceedings of the National Academy of Sciences, 1996
- Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenzaVaccine, 1990
- Duration of circulating antibody and immunity following infection with equine influenza virusVeterinary Record, 1988
- Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes.Proceedings of the National Academy of Sciences, 1985